Type 1 Diabetes Mellitus – Genetics and Environmental Factors Study

Dr. Adriana Carrillo-Iregui, pediatric endocrinologist within the Division of Pediatric Endocrinology at Nicklaus Children’s Hospital discusses the TEDDY study (The Environmental Determinants of Diabetes in the Young),  a national study to find out why type 1 diabetes mellitus (T1DM) is on the rise in children.  Early data shows that genetic predisposition and environmental factors play a role in the cause of T1 diabetes.

Read More

Coronary Microvascular Dysfunction (CMD)

Dr. C. Noel Bairey Merz, MD, Director of the Barbra Streisand Women’s Heart Center, the Linda Joy Pollin Women’s Heart Health Program, the Erika J. Glazer Women’s Heart Research Initiative, and the Preventive Cardiac Center at the Smidt Cedars-Sinai Heart Institute discusses coronary microvascular dysfunction (CMD), and how to identify and assist patients living with CMD against the backdrop of a pandemic.  She talks about what cardiologists and general practitioners should know about CMD and its warning signs, and the developing treatment options in the space.

Read More

FibroGen – Late-Breaking Roxadustat Safety Results at Kidney Week 2020

Dr. Lynda Szczech, VP of Clinical Development and Medical Affairs at FibroGen discusses new data presented at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined on roxadustat, the company’s investigational first-in-class oral treatment for anemia in patients with chronic kidney disease (CKD).  These data will build upon roxadustat’s well-defined efficacy and safety profile.  If approved in December 2020, roxadustat will be the first new anemia treatment option for CKD patients in about 30 years. Its oral formulation could make anemia management more convenient for patients and limit time spent in transfusion facilities, an especially important consideration during flu season and the COVID-19 pandemic. 

Read More

Merck and Sanofi Pasteur Data on Attitudes Toward Early-Childhood Combination Vaccinations

Dr. Michelle Goveia, MD, Executive Director, Global Medical and Scientific Affairs at Merck Vaccines and Dr. Monica Mercer, MD, Senior Director, Scientific and Medical Affairs at Sanofi Pasteur, discuss new data presented at the IDWeek 2020 virtual meeting on physician and parental attitudes about the use of early-childhood combination vaccines and the potential implications for timely completion of the CDC recommended Child and Adolescent immunization schedule.

Read More

Blue Water Vaccines – Universal Influenza Vaccine

Joseph Hernandez, Founder and CEO of Blue Water Vaccines discusses the company’s development of a universal influenza vaccine.  Current research and development of this vaccine show that two doses are needed to focus the immune response on the regions of limited variability, which could provide life-long protection against influenza strains for most patients in comparison to the current yearly vaccine that’s administered, which only help about 50% of those who get it.

Read More

Step One Foods – Cholesterol Management and Diet

Dr. Elizabeth Klodas, MD., Founder and Chief Medical Officer of Step One Foods™ discusses a new survey that shows cardiologists may be too quick to prescribe statin drugs to their patients rather than first addressing natural ways to control their cholesterol, such as changing their diet.  Without discussing diet, clinicians often over-prescribe medications to patients who would be better suited for nutritional interventions or a combination of both.  She also talks about why she decided to start her own business as a cardiologist.

Read More

GeneSight – Seniors and Depression

A new nationwide survey finds that nearly two-thirds (61%) of Americans over age 65 who have concerns about having depression say they won’t seek treatment – with a third thinking they can just “snap out of it” on their own.  Dr. Mark Pollack, past president of the Anxiety and Depression Association of America and now Chief Medical Officer of Myriad Neuroscience discusses a way to provide timely and effective treatment with the GeneSight test that uses a patient’s DNA to help their doctor make more informed recommendations. 

Read More

StemBioSys – Cartox – CELLvo Matrix Plus

Bob Hutchens, CEO of StemBioSys, Inc., developers of advanced stem cell technologies discusses research, which was recently published in peer-reviewed journal “Nature Scientific Reports” (Nov 2020), that demonstrates that CELLvo™ Matrix Plus, a jointly developed platform with Cartox, Inc., enables the widescale testing of experimental drugs via human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) and enables maturation in seven days compared to the current partial hiPSC-CM maturation within 30 to 100 days. Matrix Plus offers the potential to significantly reduce (and one day eliminate) the need to sacrifice animals for preclinical safety studies.

Read More